NEXGEL, Inc. NXGL PHARMA
Company Overview
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 31.5% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $11.42M (+31.5% YoY); net profit $-3.00M.
- Trailing 12 Months Year-on-year growth — revenue +27.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.46% |
| 1 Year: | 27.80% |
Stock Price Performance
| 1 Year: | -87.61% |
| 6 Months: | -73.69% |
| 3 Months: | -46.04% |
| 1 Month: | -21.76% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.5% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 89.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NXGL NEXGEL, Inc. PHARMA | 0.30 | -0.41 | $2.92M | 0.00% | -44.66% | -115.06% | 31.46% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 620.00K | 1.17M | 1.22M | 1.27M | 1.44M | 2.94M | - | 2.81M | 2.88M | 2.93M | 2.80M | 2.65M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.62M | 1.63M | 1.69M | 1.98M | 1.59M |
| Gross Profit | - | 285.00K | -10.00K | -108.00K | -66.00K | 74.00K | 67.00K | -85.00K | -27.00K | -42.00K | 4.00K | -57.00K | -22.00K | 101.00K | 148.00K | -57.00K | 175.00K | 344.00K | 160.00K | 293.00K | 1.16M | - | 1.19M | 1.26M | 1.24M | 819.00K | 1.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.97M | 1.89M | 1.97M | 2.03M | 2.02M |
| Operating Income | - | -287.00K | - | -612.00K | -1.07M | 74.00K | -509.00K | -540.00K | -535.00K | -520.00K | -553.00K | -610.00K | -812.00K | -718.00K | -1.04M | -883.00K | -762.00K | -612.00K | -871.00K | -1.05M | -788.00K | - | -777.00K | -636.00K | -725.00K | -1.21M | -958.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -485.00K | -566.00K | -613.00K | -523.00K | -657.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00K | 21.00K | 21.00K | - | 2.00K | 42.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -678.00K | -640.00K | -647.00K | -928.00K | -871.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -369.00K | -288.00K | -754.00K | -612.00K | -1.07M | 74.00K | -507.00K | -530.00K | -545.00K | -704.00K | -825.00K | -1.14M | -1.84M | -1.03M | -1.23M | -814.00K | -695.00K | -550.00K | -853.00K | -885.00K | -693.00K | - | -712.00K | -665.00K | -653.00K | -970.00K | -927.00K |
| Diluted EPS | - | - | -0.15 | -0.12 | -0.21 | -0.01 | -0.01 | -0.01 | -0.01 | -0.25 | -0.28 | -0.38 | -0.33 | -0.19 | -0.22 | -0.15 | -0.12 | -0.10 | -0.14 | -0.14 | -0.11 | - | -0.09 | -0.09 | -0.08 | - | -0.11 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 7.00K | 10.00K | - | 24.00K | 111.00K | 193.00K | 29.00K | 55.00K | 6.00K | 2.00K | 76.00K | - | - | 1.00K | - | 7.00K | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21M | 717.00K | 674.00K | - | 2.05M | 4.09M | 8.69M | 11.42M |
| Cost of Revenue | - | - | - | - | 1.79M | 3.71M | 5.94M | 6.91M |
| Gross Profit | 514.00K | -137.00K | -291.00K | - | 256.00K | 374.00K | 2.75M | 4.51M |
| Operating Expenses | - | - | - | - | 3.60M | 3.85M | 6.30M | 7.86M |
| Operating Income | -1.89M | -1.92M | -2.26M | - | -3.35M | -3.48M | -3.55M | -3.35M |
| EBITDA | - | - | - | - | -3.11M | -2.73M | -2.72M | -2.12M |
| Interest Expense | - | - | - | - | 1.34M | 15.00K | 81.00K | 34.00K |
| Pretax Income | - | - | - | - | -4.75M | -3.19M | -3.46M | -2.89M |
| Tax Provision | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -1.89M | -1.92M | -2.26M | - | -4.75M | -3.16M | -3.28M | -3.00M |
| Diluted EPS | -0.38 | -0.14 | -1.05 | - | -0.85 | -0.56 | -0.50 | -0.38 |
| R&D Expense | - | - | - | 31.00K | 367.00K | 103.00K | 78.00K | 2.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Mar 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 739.00K | 1.89M | 2.26M | - | - | 10.36M | 9.96M | 10.98M | 10.46M |
| Current Assets | - | - | - | - | - | - | 7.50M | 5.05M | 5.11M | 4.34M |
| Cash & Equivalents | - | 0 | 261.00K | 32.00K | - | - | 1.10M | 2.70M | 1.81M | 317.00K |
| Inventory | - | - | - | - | - | - | 502.00K | 1.32M | 1.75M | 2.11M |
| Receivables | - | - | - | - | - | - | 222.00K | 633.00K | 933.00K | 673.00K |
| Total Liabilities | - | 458.00K | 1.51M | 2.19M | - | - | 2.72M | 4.79M | 4.90M | 5.57M |
| Current Liabilities | - | 407.00K | 800.00K | 1.33M | - | - | 859.00K | 2.55M | 2.47M | 2.96M |
| Long Term Debt | - | - | - | - | 127.40K | - | 268.00K | 513.00K | 588.00K | 489.00K |
| Total Debt | - | - | - | - | - | - | 2.08M | 2.80M | 2.83M | 3.09M |
| Total Equity | 625.00K | 281.00K | 380.00K | 71.00K | - | - | 7.64M | 4.70M | 5.75M | 4.46M |
| Shares Outstanding | - | - | - | - | - | - | 5.58M | 5.74M | 7.64M | 8.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.54M | -1.81M | -1.80M | - | -2.99M | -3.24M | -3.87M | -1.31M |
| Investing Cash Flow | - | 0 | -312.00K | - | -5.59M | 4.46M | -775.00K | -68.00K |
| Financing Cash Flow | 1.54M | 2.08M | 1.88M | - | -3.66M | 379.00K | 3.75M | 630.00K |
| Capital Expenditure | - | -0 | -312.00K | - | -96.00K | -696.00K | -443.00K | -68.00K |
| Free Cash Flow | - | -1.81M | -2.11M | - | -3.09M | -3.93M | -4.31M | -1.38M |
| Net Change in Cash | - | - | - | - | -12.25M | 1.60M | -893.00K | -749.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 23.2% | -19.1% | -43.2% | - | 12.5% | 9.1% | 31.6% | 39.5% |
| Operating Margin % | -85.3% | -268.3% | -335.3% | - | -163.5% | -85.0% | -40.9% | -29.3% |
| Net Margin % | -85.3% | -268.2% | -335.9% | - | -231.7% | -77.2% | -37.8% | -26.3% |
| ROE % | -671.9% | -506.1% | -3,188.7% | - | -62.1% | -67.2% | -57.0% | -67.3% |
| ROCE % | -568.7% | -176.5% | -244.3% | - | -35.2% | -46.9% | -41.7% | -44.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP | 0.87% | 85.14K | $22.63K |
| 2 | Virtu Financial LLC | 0.81% | 79.13K | $21.03K |
| 3 | Geode Capital Management, LLC | 0.74% | 71.86K | $19.10K |
| 4 | HRT Financial LP | 0.71% | 69.48K | $18.47K |
| 5 | Morgan Stanley | 0.56% | 54.98K | $14.61K |
| 6 | Vanguard Capital Management LLC | 0.50% | 48.92K | $13.00K |
| 7 | Citadel Advisors Llc | 0.42% | 40.98K | $10.89K |
| 8 | Vanguard Fiduciary Trust Co | 0.35% | 34.04K | $9.05K |
| 9 | UBS Group AG | 0.25% | 24.73K | $6.57K |
| 10 | Jane Street Group, LLC | 0.21% | 20.61K | $5.48K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NXGL
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
LANGHORNE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: “NXGL”) today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve l…
NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp
NEXGEL (NASDAQ:NXGL) reported second-quarter 2026 revenue of $3. 69 million and a net loss of $2.
NEXGEL Reports Second Quarter 2026 Financial Results
LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel p…
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthca…
Nexgel (NXGL) Q1 2026 Earnings Transcript
On today's call, I would like to provide an overview of our first quarter 20 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid April. The business …
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-count…
NXGL — Frequently Asked Questions
What is the current share price of NEXGEL, Inc. (NXGL)?
As of 2026-09-19 21:16 PDT, NEXGEL, Inc. (NXGL) trades at $0.30 on NasdaqCM. Its 52-week range is $0.30 to $2.78.
What is the market capitalisation of NXGL?
NEXGEL, Inc. (NXGL) has a market capitalisation of $2.92M on NasdaqCM.
What is the P/E ratio of NXGL?
NXGL trades at a trailing price-to-earnings (P/E) ratio of -0.41. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.52.
What is the return on equity (ROE) of NXGL?
NXGL has a return on equity (ROE) of -115.06%. Its return on capital employed (ROCE) is -44.66%.
Is NXGL a good stock to buy?
This page provides a data-driven analysis of NEXGEL, Inc. (NXGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.